PRINCETON, N.J. & TOKYO--(BUSINESS WIRE)-- Bristol-Myers Squibb Company (NYSE: BMY) and Otsuka Pharmaceutical Co., Ltd., announced today that the U.S. Food and Drug Administration (FDA) has approved ...
Otsuka Pharmaceutical Co., Ltd., and Bristol-Myers Squibb Company announced today that the US FDA approved the supplemental New Drug Application for ABILIFY for the acute treatment of manic and mixed ...
The approval of medicines called second-generation antipsychotics has allowed bipolar I and some conditions that come with it to be treated. A person who has bipolar I disorder can go through various ...
Hosted on MSN
9 Side Effects of Abilify to Know
Abilify (aripiprazole) is a prescription atypical antipsychotic that treats depression, schizophrenia, bipolar disorder, irritability related to autism, and specific Tourette's symptoms. While most ...
Approval provides patients with schizophrenia the ability to access the efficacy and safety profile of oral aripiprazole in a once-monthly formulation. Relapse prevention is an important consideration ...
Abstract and Introduction Clinical Profile of Aripiprazole as Reflected by Clinical Trial Data Use of Aripiprazole in the Treatment of Schizophrenia: Consensus Report Conclusion References Control of ...
Abilify Asimtufii (aripiprazole) is prescribed to help treat schizophrenia and bipolar I disorder. The drug comes as a suspension (a liquid mixture) that a healthcare professional injects into a ...
Adding another antidepressant to the mix was more helpful than switching agents in older adults with treatment-resistant depression, a two-step, open-label trial suggested. In the first step of the ...
NEW YORK (MedscapeWire) May 29 — The investigational antipsychotic aripiprazole may change the treatment approach to schizophrenia, according to several studies presented on May 22-25 at the 155th ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback